Syros Pharmaceuticals Inc. | |
Stock Exchange | Frankfurt Stock Exchange |
EPS |
- |
Market Cap |
- |
Shares Outstanding |
33.65 M |
Public Float |
19.37 M |
Syros Pharmaceuticals Inc. | |
Stock Exchange | NASDAQ Stock Market |
EPS |
$1.92 |
Market Cap |
$280.15 M |
Shares Outstanding |
42.44 M |
Public Float |
21.53 M |
Address |
620 Memorial Drive Cambridge Massachusetts 02139 United States |
Employees | - |
Website | http://www.syros.com |
Updated | 07/08/2019 |
Syros Pharmaceuticals, Inc. engages in the development of novel gene control therapies for cancer and other diseases. It has developed a proprietary platform that is designed to systematically and efficiently analyze unexploited region of DNA in human disease tissue to identify and drug novel targets linked to genomically defined patient populations. The company focuses on developing treatments for cancer and immune mediated diseases and is building a pipeline of gene control medicines. |